tiprankstipranks
Advertisement

BKIE - ETF AI Analysis

Compare

Top Page

BKIE

BNY Mellon International Equity ETF (BKIE)

Rating:66Neutral
Price Target:
BKIE, the BNY Mellon International Equity ETF, has a solid overall rating driven mainly by strong, diversified holdings like Novartis, HSBC, and AstraZeneca, which show healthy financial performance, positive earnings sentiment, and generally reasonable valuations. Some positions such as Shell and Mitsubishi UFJ add value but come with risks like weaker revenue and cash flow growth or high leverage, and the fund’s focus on large international financial and healthcare names means its results are sensitive to global economic and sector-specific conditions.
Positive Factors
Strong Recent Performance
The ETF has shown solid gains so far this year and over the past month, indicating positive recent momentum.
Broad International Diversification
Holdings spread across many countries such as Japan, the UK, Europe, Canada, and Australia help reduce the impact of weakness in any single market.
Low Expense Ratio
The fund charges a very low fee, which helps investors keep more of their returns over time.
Negative Factors
Limited U.S. Exposure
With only a modest allocation to U.S. stocks, the ETF may lag if the U.S. market outperforms other regions.
Financial Sector Dependence
A relatively large weighting in financial companies means the fund could be more affected by stress in banks and other financial institutions.
Mixed Performance Among Top Holdings
While several leading positions have performed strongly, a few key holdings have been weak, which can drag on overall returns.

BKIE vs. SPDR S&P 500 ETF (SPY)

BKIE Summary

BKIE is the BNY Mellon International Equity ETF, which tracks the Solactive GBS Developed Markets ex United States Large & Mid Cap Index. It invests in many companies outside the U.S., across countries like Japan, the UK, France, and Australia, and covers a wide mix of sectors such as financials, industrials, and healthcare. Well-known holdings include ASML, HSBC, Nestlé, Toyota, and Shell. Someone might invest in BKIE to diversify beyond U.S. stocks and tap into growth in international markets with one simple fund. A key risk is that international stock prices can go up and down with global markets and currency swings.
How much will it cost me?The BNY Mellon International Equity ETF (BKIE) has an expense ratio of 0.04%, which means you’ll pay $0.40 per year for every $1,000 invested. This is lower than average because it’s passively managed, tracking an index rather than relying on active management strategies.
What would affect this ETF?BKIE's focus on developed markets outside the U.S. could benefit from economic recovery in Europe and Asia, as well as growth in sectors like financials and technology, which are heavily weighted in the ETF. However, potential risks include geopolitical tensions, regulatory changes in key regions, or slower-than-expected growth in international markets, which could negatively impact top holdings like ASML and Nestlé. Additionally, currency fluctuations could affect returns for U.S.-based investors.

BKIE Top 10 Holdings

BKIE leans heavily on non-U.S. blue chips, with Europe and Japan doing much of the heavy lifting. ASML is the clear engine here, rising strongly and giving the fund a powerful semiconductor tilt. Big global banks like HSBC, Royal Bank of Canada, and Mitsubishi UFJ are also climbing, helping the financials sleeve pull its weight. On the flip side, pharma giants Roche and AstraZeneca have been lagging, and even steady names like Nestlé feel more like ballast than boosters. Overall, performance is driven by a mix of tech strength and resurgent global financials.
Name
Company Name
Weight %
Market Value
Market Cap
Yearly Gain
Overall Rating
ASML Holding NV2.65%$33.71M€587.11B146.60%
76
Outperform
HSBC Holdings1.37%$17.40M£256.41B57.11%
80
Outperform
Royal Bank Of Canada1.20%$15.19M$298.33B57.45%
75
Outperform
Roche Holding AG1.16%$14.70M$328.85B28.25%
73
Outperform
Novartis AG1.12%$14.21MCHF228.20B34.46%
80
Outperform
Nestlé SA1.08%$13.72MCHF220.05B8.54%
71
Outperform
AstraZeneca1.01%$12.81M$262.47B20.99%
80
Outperform
Shell (UK)0.98%$12.40M£179.38B23.23%
73
Outperform
Mitsubishi UFJ Financial Group0.96%$12.25M¥38.84T50.92%
76
Outperform
Siemens0.86%$10.97M€201.66B16.72%
74
Outperform

BKIE Technical Analysis

Technical Analysis Sentiment
Positive
Last Price
Price Trends
50DMA
33.01
Positive
100DMA
32.31
Positive
200DMA
31.33
Positive
Market Momentum
MACD
0.09
Positive
RSI
53.50
Neutral
STOCH
43.87
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For BKIE, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 33.22, equal to the 50-day MA of 33.01, and equal to the 200-day MA of 31.33, indicating a bullish trend. The MACD of 0.09 indicates Positive momentum. The RSI at 53.50 is Neutral, neither overbought nor oversold. The STOCH value of 43.87 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for BKIE.

BKIE Peer Comparison

Comparison Results
Name
Price
Price Target
AUM
Expense Ratio
Overall Rating
$1.27B0.04%
66
Neutral
$5.86B0.25%
66
Neutral
$5.23B0.40%
68
Neutral
$4.07B0.30%
69
Neutral
$3.98B0.25%
68
Neutral
$3.54B0.16%
65
Neutral
Performance Comparison
Ticker
Company Name
Price
Change
% Change
BKIE
BNY Mellon International Equity ETF
33.47
5.40
19.24%
GSIE
Goldman Sachs ActiveBeta International Equity ETF
LVHI
Legg Mason International Low Volatility High Dividend ETF
IMTM
iShares MSCI Intl Momentum Factor ETF
IDMO
Invesco S&P International Developed Momentum ETF
INTF
iShares MSCI Intl Multifactor ETF
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents
Advertisement